1.69
price down icon2.87%   -0.05
after-market Dopo l'orario di chiusura: 1.69
loading
Precedente Chiudi:
$1.74
Aprire:
$1.76
Volume 24 ore:
231.42K
Relative Volume:
0.69
Capitalizzazione di mercato:
$22.86M
Reddito:
$1.89M
Utile/perdita netta:
$-17.92M
Rapporto P/E:
-0.2526
EPS:
-6.69
Flusso di cassa netto:
$-15.62M
1 W Prestazione:
+9.74%
1M Prestazione:
+36.29%
6M Prestazione:
+0.60%
1 anno Prestazione:
-46.69%
Intervallo 1D:
Value
$1.65
$1.76
Intervallo di 1 settimana:
Value
$1.43
$1.80
Portata 52W:
Value
$1.14
$4.29

Longeveron Inc Stock (LGVN) Company Profile

Name
Nome
Longeveron Inc
Name
Telefono
305-302-7158
Name
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Name
Dipendente
25
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
LGVN's Discussions on Twitter

Confronta LGVN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LGVN
Longeveron Inc
1.69 25.07M 1.89M -17.92M -15.62M -6.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Longeveron Inc Stock (LGVN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-06 Iniziato ROTH MKM Buy

Longeveron Inc Borsa (LGVN) Ultime notizie

pulisher
Jul 24, 2025

What analysts say about Longeveron Inc. stockPowerful market insights - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What risks could impact Longeveron Inc. stock performanceMarket-leading capital gains - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Longeveron Inc. Stock Analysis and ForecastFree Wealth Management Insights - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Longeveron Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

How Longeveron Inc. stock performs during market volatilityIntraday Trade Ideas - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Longeveron Inc. stock priceHigh-impact investment strategies - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Published on: 2025-07-22 07:30:15 - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Longeveron licenses stem cell patent for heart disease treatment - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Longeveron licenses stem cell patent for heart disease treatment By Investing.com - Investing.com Nigeria

Jul 21, 2025
pulisher
Jul 21, 2025

Longeveron Licenses US Patent for Advanced Cardiomyogenic Cell Technology from University of Miami - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease - The Manila Times

Jul 21, 2025
pulisher
Jul 21, 2025

Revolutionary Heart Disease Breakthrough: Longeveron Licenses Safer Cardiac Stem Cell Technology - Stock Titan

Jul 21, 2025
pulisher
Jul 16, 2025

What makes Longeveron Inc. stock price move sharplyFree Exclusive Stock Market Insights - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

Why Longeveron Inc. stock attracts strong analyst attentionLong Term Safe Yield Focus - Newser

Jul 15, 2025
pulisher
Jul 09, 2025

Longeveron (LGVN) gets FDA nod to start Phase 2 laromestrocel trial | PLUG SEC FilingForm 424B7 - Stock Titan

Jul 09, 2025
pulisher
Jul 09, 2025

Longeveron receives FDA approval for pediatric heart therapy IND By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Longeveron®? Announces U.S. FDA Approval of IND Application for A Phase 2 Pivotal Registration Study Evaluating Laromestrocel as A Treatment of Pediatric Dilated Cardiomyopathy - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron® announces U.S. FDA approval of IND application - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron stock soars after FDA approves IND for heart failure treatment By Investing.com - Investing.com South Africa

Jul 08, 2025
pulisher
Jul 08, 2025

Longeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough: FDA Fast-Tracks New Stem Cell Therapy for Fatal Children's Heart Condition - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

Longeveron (NASDAQ:LGVN) Shares Down 1.5% – What’s Next? - Defense World

Jul 02, 2025
pulisher
Jun 26, 2025

Longeveron appoints Than Powell as chief business officer - Investing.com

Jun 26, 2025
pulisher
Jun 26, 2025

Longeveron (LGVN) Appoints New Chief Business Officer to Lead Strategic Initiatives | LGVN Stock News - GuruFocus

Jun 26, 2025

Longeveron Inc Azioni (LGVN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):